Skip to content
DataLookout
Menu

NCT05806346

Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular Surgery

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date changed from estimate of Apr 30, 2025 to Oct 10, 2026 Show 6 more changesShow less
    • Study completion date changed from estimate of Jun 30, 2025 to Oct 23, 2026
    • Eligibility criteria expanded, about 11 words
    • Trial completed
    • Secondary endpoints: 17 to 19
    • Site details revised at 3 of 3 sites
    • Publications: details revised at 1 of 1 entry
  2. Notable Primary completion date: Aug 31, 2024 to Apr 30, 2025
    • Study sites: 1 to 3
    • Study completion date: Dec 31, 2024 to Jun 30, 2025
    • Secondary endpoints: details revised at 3 of 17 entries
    v8
  3. Minor Secondary endpoints: 12 to 17v7
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v6
  5. Notable Phase: Phase 4 to Not applicablev5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Start date: May 1, 2023 to Aug 1, 2023v4
  2. Minor Secondary endpoints revised (12)v3
  3. Notable Eligibility criteria expanded, about 1 wordv2 Show 5 more changesShow less
    • Interventions: Tranexamic acid injection (Drug), rotational thromboelastometry (Diagnostic Test) to Placebo administration (Drug), TXA administration (Drug)
    • Secondary endpoints: 4 to 12
    • Study arms: 3 to 4
    • Study description expanded, about 3 words
    • Study title shortened, about 5 words
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

postoperative bleeding
Timeframe: 24 hours

Secondary (19)

postoperative transfusion amount
postoperative transfusion rate
the lowest postoperative hemoglobin value
incidence of reoperation
amount of intraoperative cell salvage
Show 14 moreShow less
viscoelastic whole blood profile
incidence of seizure
incidence of thromboembolic complications
duration of mechanical ventilation
length of stays in the ICU and hospital
total cost
incidence of taking renal replacement therapy
incidence of acute kidney injury
incidence of postoperative delirium
incidence of applying for mechanical circulatory support
in-hospital mortality
central laboratory blood tests
Days alive at home
Fibrinolysis phenotype

Arms and interventions

Empirical 1: TXA and Placebo administrationActive comparator

Tranexamic acid administration, regardless of the result of rotational thromboelastometry. Placebo administration, at LI60 \< 85 % or A10\< 40 mm in EXTEM of rotational thromboelastometry

Empirical 2: TXA administrationActive comparator

Tranexamic acid administration, regardless of the result of rotational thromboelastometry. Placebo discard, at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry

Goal-directed 1: Placebo administrationExperimental

Placebo administration, regardless of the result of rotational thromboelastometry. Tranexamic acid administration at LI60 \< 85 % or A10 \< 40 mm in EXTEM of rotational thromboelastometry

Goal-directed 2: TXA and Placebo administrationExperimental

Placebo administration, regardless of the result of rotational thromboelastometry. Tranexamic acid discard at LI60 ≥ 85% or A10 ≥ 40 mm in EXTEM of rotational thromboelastometry

Drugs: TXA administration, Placebo administration

Sites

3 sites in 1 country